Zacks Research Downgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to Strong Sell

MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other research firms have also recently commented on MLTX. Wolfe Research cut MoonLake Immunotherapeutics from an “outperform” rating to an “underperform” rating in a research report on Tuesday, September 30th. Wedbush lowered their price target on MoonLake Immunotherapeutics from $80.00 to $18.00 and set an “outperform” rating on the stock in a report on Tuesday, September 30th. Needham & Company LLC dropped their price target on MoonLake Immunotherapeutics from $66.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, September 30th. Guggenheim dropped their target price on MoonLake Immunotherapeutics from $80.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 30th. Finally, UBS Group set a $24.00 price target on shares of MoonLake Immunotherapeutics in a research report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $25.77.

MoonLake Immunotherapeutics Price Performance

Shares of NASDAQ MLTX opened at $16.71 on Tuesday. The firm has a market cap of $1.07 billion, a P/E ratio of -5.03 and a beta of 1.21. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25. The company has a 50 day moving average of $14.15 and a 200 day moving average of $29.78.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Wednesday, November 5th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.21). During the same quarter last year, the firm posted ($0.56) earnings per share. As a group, research analysts expect that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Insider Transactions at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 130,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the completion of the transaction, the insider directly owned 72,908 shares in the company, valued at $1,099,452.64. This represents a 64.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Da Silva Jorge Santos sold 130,000 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the sale, the chief executive officer directly owned 2,948,577 shares of the company’s stock, valued at approximately $44,464,541.16. This trade represents a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 402,908 shares of company stock valued at $5,987,162. Corporate insiders own 12.02% of the company’s stock.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Hedge funds have recently modified their holdings of the stock. FNY Investment Advisers LLC bought a new stake in MoonLake Immunotherapeutics in the 3rd quarter valued at $28,000. Bank of America Corp DE grew its position in shares of MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after purchasing an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after purchasing an additional 3,166 shares during the last quarter. Covestor Ltd purchased a new stake in shares of MoonLake Immunotherapeutics in the third quarter worth about $46,000. Finally, BNP Paribas Financial Markets boosted its stake in MoonLake Immunotherapeutics by 18.9% during the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after buying an additional 1,158 shares during the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.